1103P Long-term survival of real-world advanced melanoma patients treated with targeted therapy

Abstract

Background:The phase III IMspire150 study (NCT02908672) demonstrated that combination therapy with inhibitors of PD-L1 (atezolizumab [A]), BRAF (vemurafenib [V]), and MEK (cobimetinib [C]) improved investigator-assessed PFS vs placebo (P)+V+C (hazard ratio [HR] 0.78; 95% CI 0.63-0.97; log-rank P¼0.025). An exploratory analysis was conducted to define efficacy outcomes in key prognostic subgroups defined by baseline PD-L1 and LDH status.